Calnexin is a Ca2+-binding transmembrane chaperone of the endoplasmic reticulum that recognizes Glc1Man5-9GlcNAc2 oligosaccharides on folding glycoproteins as well as non-native elements of the polypeptide backbone. This latter mode of recognition enables calnexin to suppress the aggregation of both glycosylated and nonglycosylated substrates. The luminal portion of calnexin (S-Cnx) consists of two domains, a globular lectin domain and an extended arm domain. To understand the function of these domains during the interaction of calnexin with non-native protein conformers, we tested deletion mutants of S-Cnx for their abilities to suppress the aggregation of nonglycosylated firefly luciferase. The arm domain alone exhibited no capacity to suppress aggregation. However, stepwise truncation of the arm domain in S-Cnx resulted in a progressive reduction in aggregation suppression potency to the point where the globular domain alone exhibited 25% potency. To characterize the polypeptide-binding site, we used hydrophobic peptides that were competitors of the ability of S-Cnx to suppress luciferase aggregation. Direct binding experiments revealed a single site of peptide binding in the globular domain (Kd = 0.9 microm) at a location distinct from the lectin site. Progressive truncation of the arm domain in S-Cnx had no effect on the binding of small peptides but reduced the binding affinity of S-Cnx for large, non-native protein substrates. Because protein substrates exhibited no binding to the isolated arm domain, our findings support a model in which calnexin suppresses aggregation through a polypeptide-binding site in its globular domain, with the arm domain enhancing aggregation suppression by sterically constraining large substrates.
No takes yet. Share an insight, caveat, or question.
Brockmeier et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: